Post by beebs on Jun 13, 2012 16:22:59 GMT -5
The article below discusses the link between new antipsychotics
and diabetes in teenagers. It will probably take years before
the link is made for adults!
Newer Antipsychotics Raise Diabetes Risk in Youth
Jim Kling
June 10, 2012 (Philadelphia, Pennsylvania) — Second-generation antipsychotics (SGAs), particularly ziprasidone, raise the risk for type 2 diabetes (T2D) in children and adolescents, according to research presented here at the American Diabetes Association (ADA) 72nd Scientific Sessions.
Many studies have shown that SGAs can increase diabetes risks in adults, but "children have not been explored that much," Avnish Tripathi, MD, MPH, a doctoral candidate at the University of South Carolina School of Public Health, Columbia, who presented the research, told Medscape Medical News.
The researchers conducted a study of more than 4000 patients 17 years and younger who were served through the South Carolina State Medicaid Program between 1996 and 2006, and who had been newly prescribed at least 1 of the following SGAs during that time: aripiprazole, ziprasidone, quetiapine, risperidone, and olanzapine.
The study included a 24-month "SGA-free" baseline period immediately before the first SGA was prescribed. The researchers defined incidence of T2D as 2 or more initial service encounters at least 30 days apart, marked by International Classification of Diseases, Ninth Revision, codes for T2D. The researchers used similar criteria to establish comorbid conditions such as obesity, dyslipidemia, and hypertension.
The study included 4140 patients (median age, 11 years; interquartile range, 4 - 11 years), of whom 176 participants (4.3%) were diagnosed with new-onset T2D.
The researchers conducted Cox proportional hazards analysis with time-dependent covariates and found increased risk for T2D in females (hazard ratio
, 1.78; 95% confidence interval [CI], 1.30 - 2.44); African Americans (HR, 1.52; 95% CI, 1.07 - 1.25), overweight or obese individuals (HR, 4.19; 95% CI, 2.87 - 6.11), and patients with dyslipidemia (HR, 3.33; 95% CI, 1.76 - 6.30).
Compared with patients with no exposure to SGAs, the investigators also noted increased risk associated with use of aripiprazole (HR, 2.92; 95% CI, 1.08 - 7.90) or ziprasidone (HR, 3.56; 95% CI, 1.61 - 7.89). Mood stabilizers also increased risk (HR, 1.64; 95% CI, 1.13 - 2.37) compared with those with no exposure.
A multivariable marginal structural model indicated a higher causal association of overweight/obesity (HR, 5.59; 95% CI, 2.71 - 11.51) and ziprasidone (HR, 5.12; 95% CI, 1.15 - 22.70). Cont/...
www.medscape.com/viewarticle/765403?sssdmh=dm1.792721&src=nldne